Pyxis Oncology Inc [PYXS] stock is trading at $1.73, down -48.66%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PYXS shares have lost -60.77% over the last week, with a monthly amount drifted -63.35%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on September 04, 2025, and set its price target to $5. On November 21, 2024, downgrade downgraded it’s rating to Mkt Perform. Stephens started tracking the stock assigning a Overweight rating and suggested a price target of $13 on November 08, 2024. Stifel initiated its recommendation with a Buy and recommended $10 as its price target on August 08, 2024. In a note dated February 09, 2024, BTIG Research initiated an Buy rating and provided a target price of $8 on this stock.
Pyxis Oncology Inc [PYXS] stock has fluctuated between $0.83 and $5.55 over the past year. Currently, Wall Street analysts expect the stock to reach $6.67 within the next 12 months. Pyxis Oncology Inc [NASDAQ: PYXS] shares were valued at $1.73 at the most recent close of the market. An investor can expect a potential return of 285.55% based on the average PYXS price forecast.
Analyzing the PYXS fundamentals
Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -17.07%, Pretax Profit Margin comes in at -15.91%, and Net Profit Margin reading is -15.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.92, Equity is -1.02 and Total Capital is -1.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.50 points at the first support level, and at 1.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.93, and for the 2nd resistance point, it is at 2.14.
Ratios To Look Out For
For context, Pyxis Oncology Inc’s Current Ratio is 4.29. As well, the Quick Ratio is 4.29, while the Cash Ratio is 0.46. Considering the valuation of this stock, the price to sales ratio is 38.20, the price to book ratio is 1.56.
Transactions by insiders
Recent insider trading involved HUMPHREY RACHEL, Director, that happened on Apr 21 ’25 when 13896.0 shares were purchased. Director, HUMPHREY RACHEL completed a deal on Apr 17 ’25 to buy 200.0 shares. Meanwhile, Director HUMPHREY RACHEL bought 1400.0 shares on Apr 14 ’25.
